Insulin glargine and malignancy: an unwarranted alarm (Q39361047)

11 September 2017

title

Insulin glargine and malignancy: an unwarranted alarm (English)

1 reference

11 September 2017

1 reference

2

Liam Smeeth

1 reference

11 September 2017

Stuart J Pocock

1

1 reference

11 September 2017

language of work or name

English

0 references

publication date

17 July 2009

1 reference

11 September 2017

1 reference

11 September 2017

volume

374

1 reference

11 September 2017

issue

9689

1 reference

11 September 2017

page(s)

511-513

1 reference

Does diabetes therapy influence the risk of cancer?

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961307-6

7 January 2021

Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961307-6

7 January 2021

The influence of glucose-lowering therapies on cancer risk in type 2 diabetes

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961307-6

7 January 2021

Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961307-6

7 January 2021

When are observational studies as credible as randomised trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961307-6

7 January 2021

Randomized trials or observational tribulations?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2809%2961307-6

7 January 2021

10.1016/S0140-6736(09)61307-6

Identifiers

DOI

1 reference

11 September 2017

1 reference